Prostate Health in Senior Men

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that is nearly universal in aging men — affecting 50% of men by age 60, 70% by age 70, and over 80% by age 80. The prostate surrounds the urethra (the tube carrying urine out of the bladder), so as it enlarges, it compresses the urethra and creates a 'kink in a garden hose' effect — slowing urine flow, causing the bladder to work harder, and eventually producing the characteristic lower urinary tract symptoms. The underlying cause is hormonal: testosterone is converted to dihydrotestosterone (DHT) in the prostate, and DHT drives prostate cell growth. With aging, testosterone levels fall but relative DHT activity changes in ways that promote prostate tissue growth. BPH is entirely distinct from prostate cancer — having BPH does not mean a man has or will develop cancer, and the two conditions are diagnosed and treated separately. However, both produce urinary symptoms, which is why they can be confused.

This is one of the most important medication safety questions for senior men. Alpha-blockers (tamsulosin/Flomax, alfuzosin/Uroxatral, doxazosin, terazosin) are the most commonly prescribed BPH medications and the most effective for rapid symptom relief — but ALL of them are on the AGS Beers Criteria as potentially inappropriate for older adults due to the risk of orthostatic hypotension (blood pressure dropping when standing up), dizziness, and falls. Tamsulosin is the most prostate-selective alpha-blocker and has lower blood pressure effects than doxazosin or terazosin, making it somewhat safer for seniors — but it still carries fall risk, and must be disclosed to any ophthalmologist before cataract surgery (it causes intraoperative floppy iris syndrome, which can complicate the surgery). 5-alpha reductase inhibitors (finasteride, dutasteride) are NOT on the Beers Criteria and have no orthostatic hypotension effect — but they take 6–12 months to work (they shrink the prostate gradually), they lower PSA by ~50% (important for cancer screening), and they cause sexual side effects in 5–15% of users. For seniors at high fall risk, discussing medication choice with the urologist — particularly the option of minimally invasive procedures (UroLift, Rezum) that eliminate the need for long-term BPH medication — may be worthwhile.

The International Prostate Symptom Score (IPSS) is a validated 7-question self-reported questionnaire that quantifies the severity of lower urinary tract symptoms from BPH. Each of seven symptoms is scored 0–5 based on frequency, for a maximum score of 35 plus a separate quality-of-life question. Interpretation: 0–7 points = mild symptoms (watchful waiting is appropriate); 8–19 points = moderate symptoms (medication or minimally invasive treatment recommended); 20–35 points = severe symptoms (medication plus consideration of surgical procedure). The IPSS is not specific to BPH — it measures any lower urinary tract symptoms — so other causes (bladder overactivity, urinary infection, bladder cancer, neurogenic bladder from diabetes or spinal stenosis) must be ruled out by the urologist. Many primary care offices administer the IPSS at annual preventive visits for men over 50; if yours hasn't, you can complete it online or ask the office for the questionnaire.

This is a genuinely complex medical decision with reasonable arguments on both sides, and the right answer depends on the individual man's health, life expectancy, and values. The USPSTF currently advises against routine PSA screening for men 70 and older — the rationale being that most prostate cancers detected in this age group are low-grade, slow-growing tumors that would not cause death or symptoms within the man's remaining lifespan, while treatment carries real risks: urinary incontinence, erectile dysfunction, and the harms of biopsy itself (infection, bleeding, anxiety). On the other hand, some 70+ men are in excellent health with 15–20 year life expectancies and legitimately want to know whether they have a high-grade cancer that could cause death or severe bone pain from metastasis. Current clinical practice: For men 70–74 in excellent health, many urologists continue PSA surveillance with a focus on PSA velocity and free:total PSA ratio to distinguish low from high-grade disease. For men 75+, most guidelines recommend against initiating new PSA screening, though continuing an established screening program in a healthy man is reasonable. The conversation should be had explicitly with the primary care physician — not defaulting to screening or non-screening, but a genuine discussion of the specific man's health status, life expectancy, and preferences.

All three procedures treat BPH by relieving urethral obstruction, but they differ significantly in mechanism, recovery, and side effects: TURP (Transurethral Resection of the Prostate): removes prostate tissue surgically using an electrosurgical scope passed through the urethra. Gold standard; highly effective; durable for 10–15 years. Requires spinal or general anesthesia and 1–2 night hospital stay. Main side effect: retrograde ejaculation (semen goes backward into the bladder) occurs in ~70% — permanent, but medically harmless. UroLift (Prostatic Urethral Lift): tiny permanent implants hold the prostate lobes away from the urethra without cutting or removing tissue. Office procedure or same-day surgery under local anesthesia or light sedation. Key advantage: preserves ejaculatory function (critical differentiator for many men). Less effective than TURP for very large prostates; some men need re-treatment at 5 years. Rezum (Water Vapor Therapy): steam injected through the urethra destroys excess prostate tissue; tissue resorbs over 3 months. Outpatient procedure; preserves ejaculatory function in 92% of men. Slightly longer time to full symptom improvement than UroLift (3–4 months) because the tissue resorbs gradually. Effective for men with challenging middle lobe anatomy that makes UroLift less suitable. The right procedure depends on prostate size, anatomical features on ultrasound or MRI, the patient's surgical risk, ejaculatory function priorities, and institutional expertise.

Acute urinary retention (AUR) is the sudden complete inability to urinate — a urological emergency requiring immediate intervention. It typically presents as severe lower abdominal pain and distension, extreme discomfort, inability to pass any urine despite intense urge, and a visibly or palpably distended bladder. AUR in men is most commonly caused by severe BPH, though it can also be triggered by: constipation (fecal impaction compresses the bladder outlet); certain medications — anticholinergics, decongestants, opioids, antihistamines, and tricyclic antidepressants all reduce bladder contractility; alcohol (urethral relaxation + high urine volume); cold weather (sympathetic stimulation of alpha receptors); recent surgery and anesthesia; or urinary infection. Treatment is emergency bladder decompression by urethral catheterization — this is immediately relieving for the patient and must not be delayed. After catheterization, the cause is investigated. Alpha-blocker medication is typically started before the catheter is removed, as it improves the chance of successful voiding trial. If AUR recurs, a BPH procedure is usually recommended. Go to an emergency room immediately — a bladder retained for hours at very high pressure can cause permanent kidney damage.

Treatment for prostate cancer is tailored to the cancer's grade and stage, the patient's age, overall health, and the estimated 10-year life expectancy — because prostate cancer treatment carries significant side effects (erectile dysfunction, urinary incontinence) that must be weighed against survival benefit: Active surveillance: For low-risk and select favorable intermediate-risk cancers, active surveillance (PSA tests every 6 months, MRI, and repeat biopsy at intervals) allows monitoring without treatment. Studies show that 30–40% of men on active surveillance never require treatment during their lifetime. This approach is particularly appropriate for men 70+ with low-grade disease. Radiation therapy: External beam radiation (IMRT, stereotactic body radiation) or brachytherapy (radioactive seed implants). Effective for localized disease; urinary and bowel side effects; excellent option for seniors who cannot have surgery. Androgen deprivation therapy (ADT): Reduces testosterone to castrate levels via LHRH agonist (leuprolide/Lupron) or antagonist (degarelix/Firmagon). Used for metastatic disease, high-risk local disease with radiation, and recurrent disease. Significant side effects: hot flashes, osteoporosis, weight gain, metabolic syndrome, cognitive changes, cardiovascular risk, depression. Requires careful monitoring. Radical prostatectomy (robotic or open surgery): Removes the entire prostate. Considered for healthy men under 75 with intermediate-high risk localized disease and life expectancy >10 years. Urinary incontinence (usually temporary, 3–18 months) and erectile dysfunction (often permanent, 30–80% depending on surgical technique) are common. The key principle: a 75-year-old with multiple comorbidities and a Gleason 6 (Grade Group 1) prostate cancer is almost certainly best served by active surveillance — treatment is unlikely to extend life and will impair quality of life. A 70-year-old in excellent health with Gleason 8 (Grade Group 4) cancer is best served by definitive treatment. Decisions should be made with a urological oncologist.

Urinary tract infections in men are far less common than in women — the much longer male urethra provides a natural barrier to ascending bacteria. When a man does develop a UTI (particularly a recurrent one), it is generally considered significant and warrants investigation for an underlying anatomical or functional cause. The most common explanation in older men is BPH causing incomplete bladder emptying — retained urine creates a perfect bacterial growth medium. Other causes include: prostatitis, urethral stricture, bladder stones, urinary catheter (indwelling catheters predictably cause UTI), or immunosuppression from diabetes, steroids, or chemotherapy. Men with recurrent UTIs should be evaluated by a urologist with a post-void residual measurement (to detect incomplete bladder emptying), urine culture with antibiotic sensitivities, and possibly cystoscopy. Unlike women — where post-menopausal UTIs are often treated empirically — UTIs in senior men warrant urine culture before antibiotic selection. Complicated UTIs in men that spread to the prostate (prostatitis) or kidney (pyelonephritis) or bloodstream (urosepsis) can be life-threatening and usually require hospitalization and IV antibiotics.